Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
Identifieur interne : 001662 ( Main/Exploration ); précédent : 001661; suivant : 001663Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
Auteurs : RBID : pubmed:20225244English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Dihydroxyphenylalanine (analogs & derivatives), Dihydroxyphenylalanine (diagnostic use), Female, Humans, Male, Middle Aged, Neuroendocrine Tumors (diagnosis), Neuroendocrine Tumors (surgery), Octreotide (analogs & derivatives), Octreotide (diagnostic use), Positron-Emission Tomography (methods), Prospective Studies, Radiopharmaceuticals (diagnostic use), Sensitivity and Specificity, Tomography, Spiral Computed (methods).
- MESH :
- chemical , analogs & derivatives : Dihydroxyphenylalanine, Octreotide.
- chemical , diagnostic use : Dihydroxyphenylalanine, Octreotide, Radiopharmaceuticals.
- diagnosis : Neuroendocrine Tumors.
- methods : Positron-Emission Tomography, Tomography, Spiral Computed.
- surgery : Neuroendocrine Tumors.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Prospective Studies, Sensitivity and Specificity.
Abstract
Accurate knowledge of tumour presence and location is essential to treat neuroendocrine tumours (NETs). Standard imaging has been hampered by low sensitivity and lack of spatial resolution. This study assessed prospectively the diagnostic value and impact of combined 6-[18F]fluorodihydroxyphenylalanine positron emission tomography-computed tomography (18F-DOPA-PET/CT) in the management of NET.
DOI: 10.1002/bjs.6937
PubMed: 20225244
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.</title><author><name sortKey="Schiesser, M" uniqKey="Schiesser M">M Schiesser</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, University Hospital Zurich, Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Surgery, University Hospital Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Veit Haibach, P" uniqKey="Veit Haibach P">P Veit-Haibach</name></author><author><name sortKey="Muller, M K" uniqKey="Muller M">M K Muller</name></author><author><name sortKey="Weber, M" uniqKey="Weber M">M Weber</name></author><author><name sortKey="Bauerfeind, P" uniqKey="Bauerfeind P">P Bauerfeind</name></author><author><name sortKey="Hany, T" uniqKey="Hany T">T Hany</name></author><author><name sortKey="Clavien, P A" uniqKey="Clavien P">P-A Clavien</name></author></titleStmt><publicationStmt><date when="2010">2010</date><idno type="doi">10.1002/bjs.6937</idno><idno type="RBID">pubmed:20225244</idno><idno type="pmid">20225244</idno><idno type="wicri:Area/Main/Corpus">001A48</idno><idno type="wicri:Area/Main/Curation">001A48</idno><idno type="wicri:Area/Main/Exploration">001662</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Dihydroxyphenylalanine (analogs & derivatives)</term><term>Dihydroxyphenylalanine (diagnostic use)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuroendocrine Tumors (diagnosis)</term><term>Neuroendocrine Tumors (surgery)</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (diagnostic use)</term><term>Positron-Emission Tomography (methods)</term><term>Prospective Studies</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Sensitivity and Specificity</term><term>Tomography, Spiral Computed (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Dihydroxyphenylalanine</term><term>Octreotide</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Positron-Emission Tomography</term><term>Tomography, Spiral Computed</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Sensitivity and Specificity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Accurate knowledge of tumour presence and location is essential to treat neuroendocrine tumours (NETs). Standard imaging has been hampered by low sensitivity and lack of spatial resolution. This study assessed prospectively the diagnostic value and impact of combined 6-[18F]fluorodihydroxyphenylalanine positron emission tomography-computed tomography (18F-DOPA-PET/CT) in the management of NET.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20225244</PMID><DateCreated><Year>2010</Year><Month>04</Month><Day>15</Day></DateCreated><DateCompleted><Year>2010</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-2168</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>The British journal of surgery</Title><ISOAbbreviation>Br J Surg</ISOAbbreviation></Journal><ArticleTitle>Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.</ArticleTitle><Pagination><MedlinePgn>691-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/bjs.6937</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Accurate knowledge of tumour presence and location is essential to treat neuroendocrine tumours (NETs). Standard imaging has been hampered by low sensitivity and lack of spatial resolution. This study assessed prospectively the diagnostic value and impact of combined 6-[18F]fluorodihydroxyphenylalanine positron emission tomography-computed tomography (18F-DOPA-PET/CT) in the management of NET.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">18F-DOPA-PET/CT findings in 61 patients with suspected NET were compared with a composite reference standard including somatostatin receptor scintigraphy (SRS), magnetic resonance imaging, computed tomography, histological examination and clinical follow-up. The impact on clinical management was estimated by calculating the proportion of patients whose treatment changed as a result of 18F-DOPA-PET/CT findings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">18F-DOPA-PET/CT correctly identified 32 of 36 patients with NET. The sensitivity and specificity of 18F-DOPA-PET/CT for the detection of NET were 91 and 96 per cent respectively. Sensitivity using SRS was significantly lower (59 per cent), whereas the specificity was similar (86 per cent). In 16 (26 per cent) of the 61 patients the management was altered as a result of new findings on 18F-DOPA-PET/CT.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">18F-DOPA-PET/CT yields a high sensitivity and specificity in the detection of NET. The clinical impact was highly relevant as changes in therapy were observed in more than a quarter of the patients.</AbstractText><CopyrightInformation>Copyright 2010 British Journal of Surgery Society Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schiesser</LastName><ForeName>M</ForeName><Initials>M</Initials><Affiliation>Department of Surgery, University Hospital Zurich, Zurich, Switzerland.</Affiliation></Author><Author ValidYN="Y"><LastName>Veit-Haibach</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Muller</LastName><ForeName>M K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bauerfeind</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hany</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Clavien</LastName><ForeName>P-A</ForeName><Initials>PA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Comparative Study</PublicationType><PublicationType>Evaluation Studies</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Surg</MedlineTA><NlmUniqueID>0372553</NlmUniqueID><ISSNLinking>0007-1323</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>indium-111-octreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>2C598205QX</RegistryNumber><NameOfSubstance>fluorodopa F 18</NameOfSubstance></Chemical><Chemical><RegistryNumber>63-84-3</RegistryNumber><NameOfSubstance>Dihydroxyphenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Dihydroxyphenylalanine</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neuroendocrine Tumors</DescriptorName><QualifierName MajorTopicYN="Y">diagnosis</QualifierName><QualifierName MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, Spiral Computed</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.6937</ArticleId><ArticleId IdType="pubmed">20225244</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001662 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001662 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20225244
|texte= Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20225244" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |